BIOPHYTIS received regulatory authorizations to conduct SARA-OBS study in sarcopenia patients
Nov 22, 2016 12:30 pm UTC| Business
ROMAINVILLE, France, Nov. 22, 2016 -- BIOPHYTIS (Alternext Paris:ALBPS) a biotechnology company specialized in the development of drug candidates to treat aging diseases, announces it has received regulatory...
Global Waterborne Coatings Market will reach USD 78.24 Billion in 2021, Says ZMR
Nov 22, 2016 12:13 pm UTC| Business
Sarasota, FL, Nov. 22, 2016 -- Zion Research has published a new report titled “Waterborne Coatings Market by Resin (Acrylic, Polyester, Alkyd, Epoxy, Polyurethane, PTFE, PVDF, and PVDC), for Architectural, Automotive,...
uniQure Announces Financial Results For Third Quarter 2016 and Provides Update on Company Progress
Nov 22, 2016 12:06 pm UTC| Business
~ Strategic Review Completed to Refocus Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value ~ Updated Clinical Data on AMT-060 in Hemophilia B at Upcoming ASH Annual MeetingLEXINGTON, Mass. and...
Elbit Vision Systems Announces Third Quarter 2016 Results
Nov 22, 2016 12:00 pm UTC| Business
Revenues at $2.5 million Net Income of $528 thousand Third Quarter 2016 highlights Revenue of $2.5 million with continued sequential growth expected into Q4;Gross and operating margins at 54.9% and 22.3%,...
uniQure Announces Financial Results For Third Quarter 2016 and Provides Update on Company Progress
Nov 22, 2016 12:00 pm UTC| Business
~ Strategic Review Completed to Refocus Pipeline, Reduce Operating Costs and DeliverLong-Term Shareholder Value ~ Updated Clinical Data on AMT-060 in Hemophilia B at Upcoming ASH Annual Meeting LEXINGTON, Mass. and...
GDS Holdings Limited to Report Third Quarter 2016 Financial Results on Monday, December 5, 2016
Nov 22, 2016 12:00 pm UTC| Business
SHANGHAI, China, Nov. 22, 2016 -- GDS Holdings Limited (the “Company”) (NASDAQ:GDS), a leading developer and operator of high-performance data centers in China, today announced that it will report its third quarter 2016...
Nov 22, 2016 12:00 pm UTC| Business
NEW YORK, Nov. 22, 2016 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) today announced a positive 41-week update from its Phase 2a study in mild-to-moderate Alzheimer’s disease (AD) patients for...